Notizie AIOM – anno XVII – Pagina 38

22 Luglio 2019

Economic Burden of Cancer in the United States in 2015

July 15, 2019 - There were more than 8.7 million person-years of life lost and $94.4 billion in earnings lost due to cancer among people aged 16 to 84 in the United States in 2015. The calculation comes from a new report published by Islami et al in JAMA Oncology. Cancer ...
Leggi tutto

22 Luglio 2019

EMA takes note of the European Ombudsman’s decision on pre-submission activities

July 19, 2019 - EMA welcomes the European Ombudsman’s recognition of the value and need for scientific advice and her recommendations are in line with EMA’s ongoing initiatives to further increase transparency. Early interactions with medicine developers and ...
Leggi tutto

22 Luglio 2019

Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer

Compared with single-marker genetic testing (SMGT), multigene panel sequencing (MGPS) has the potential to identify more patients with cancer who could benefit from targeted therapies, but the effects on outcome and total cost of care are uncertain. Our goal was to estimate ...
Leggi tutto

22 Luglio 2019

Will That Pulmonary Nodule Become Cancerous? A Risk Prediction Model for Incident Lung Cancer

This prospective investigation derived a prediction model for identifying risk of incident lung cancer among patients with visible lung nodules identified on computed tomography (CT). Among 2,924 eligible patients referred for evaluation of a pulmonary nodule to the Stony ...
Leggi tutto

22 Luglio 2019

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study

To compare the survival outcomes of neoadjuvant three-dimensional conformal radiotherapy (RT) followed by hepatectomy with hepatectomy alone in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). A randomized, multicenter controlled study ...
Leggi tutto

19 Luglio 2019

Fragility Analysis of Phase III Trials Supporting FDA Approval of Anticancer Drugs

July 17, 2019 - In an analysis reported in The Lancet Oncology, Del Paggio and Tannock found that many phase III trials supporting U.S. Food and Drug Administration (FDA) approval of anticancer drugs have a low fragility index—a measure of how many people in a study ...
Leggi tutto

19 Luglio 2019

18 luglio 2019 – Avvio del procedimento di Pay-Back convenzionata 1.83% – 2° semestre 2018

19 Luglio 2019

18 luglio 2019 – Presentato in AIFA il Rapporto OsMed sull’uso dei farmaci in Italia 2018

17 Luglio 2019

17 luglio 2019 – Report monitoraggio biosimilari

17 Luglio 2019

17 luglio 2019 – AIFA inaugura il nuovo sito

LAVORIAMO CON

News

LA PREVENZIONE DEL MELANOMA: AL VIA UNA CAMPAGNA NEI COOP.FI

TUMORI: “AIFA APPROVA LA FORMULAZIONE SOTTOCUTANEA E TRE NUOVE INDICAZIONI TERAPEUTICHE DI NIVOLUMAB”

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

Notizie AIOM – anno XVII

Economic Burden of Cancer in the United States in 2015

EMA takes note of the European Ombudsman’s decision on pre-submission activities

Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer

Will That Pulmonary Nodule Become Cancerous? A Risk Prediction Model for Incident Lung Cancer

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study

Fragility Analysis of Phase III Trials Supporting FDA Approval of Anticancer Drugs

18 luglio 2019 – Avvio del procedimento di Pay-Back convenzionata 1.83% – 2° semestre 2018

18 luglio 2019 – Presentato in AIFA il Rapporto OsMed sull’uso dei farmaci in Italia 2018

17 luglio 2019 – Report monitoraggio biosimilari

17 luglio 2019 – AIFA inaugura il nuovo sito